Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

MIAMI - Pulse Biosciences, Inc. (NASDAQ:PLSE), a biotech company with a market capitalization of $1.08 billion and an ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

British Columbia's minister of health says the province has opened 26 new treatment beds for people with addictions in four ...

According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Boston Scientific Corporation (NYSE: BSX) today announced data supporting the use of the FARAPULSE™ Pulsed Field Ablation ...

A New Pacemaker Algorithm for the Treatment of Atrial Fibrillation: Results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT) Electrophysiologic Characteristics of the Spontaneous Onset and ...

Obesity can put strain on the heart, resulting in an increased risk of conditions such as atrial fibrillation, or irregular ...

Already cleared in the US for use in soft tissue ablation, Pulse Biosciences is looking to add AF to CellFX’s indication list ...